STOCK TITAN

Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Evoke Pharma, Inc. (NASDAQ: EVOK) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Dave Gonyer and CBO Matt D’Onofrio will engage in a virtual presentation on September 13, which will be available on-demand starting at 7:00 am ET.

This conference will include corporate presentations and one-on-one meetings. Interested investors can schedule calls with Evoke management via their H.C. Wainwright representative.

Positive
  • None.
Negative
  • None.

SOLANA BEACH, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R.Ph., President and Chief Executive Officer, and Matt D’Onofrio, Chief Business Officer, will participate virtually in the H.C. Wainwright 23rd Annual Global Investment Conference taking place from September 13 – 15, 2021.

 Event:H.C. Wainwright 23rd Annual Global Investment Conference
 Format:Corporate Presentation and One-on-One Meetings
 Date:Monday, September 13, 2021 (presentation)
 Location:Virtual
 Time:Available on-demand starting at 7:00 am ET to those attending the conference virtually

Investors participating in the conference who would like to schedule a one-on-one call with Evoke management may do so by contacting their H.C. Wainwright representative, or Christine Petraglia of The Ruth Group at cpetraglia@theruthgroup.com.

About Evoke Pharma, Inc.

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Visit www.EvokePharma.com for more information.

Follow GIMOTI on Facebook: https://www.facebook.com/Gimoti-metoclopramide-nasal-spray-104672345100289

Follow Evoke Pharma on Facebook: https://www.facebook.com/Evoke-Pharma-Inc-131313647029724

Follow Evoke Pharma on LinkedIn: https://www.linkedin.com/company/evoke-pharma/

Investor Contact:
The Ruth Group
Christine Petraglia
Tel: 917-633-8980
cpetraglia@theruthgroup.com

Media Contact:
The Ruth Group
Annika Parrish
Tel: 720-412-9042
aparrish@theruthgroup.com


FAQ

When will Evoke Pharma participate in the H.C. Wainwright conference?

Evoke Pharma will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, with a presentation on September 13.

What time will Evoke Pharma's presentation be available?

Evoke Pharma's presentation will be available on-demand starting at 7:00 am ET on September 13, 2021.

Who will represent Evoke Pharma at the conference?

Dave Gonyer, President and CEO, and Matt D’Onofrio, Chief Business Officer, will represent Evoke Pharma at the conference.

How can investors schedule a one-on-one meeting with Evoke Pharma management?

Investors can schedule a one-on-one call by contacting their H.C. Wainwright representative or Christine Petraglia of The Ruth Group.

What is the main focus of Evoke Pharma?

Evoke Pharma focuses on developing treatments for gastrointestinal diseases, specifically through its product GIMOTI, a nasal spray for diabetic gastroparesis.

Evoke Pharma, Inc.

NASDAQ:EVOK

EVOK Rankings

EVOK Latest News

EVOK Stock Data

6.24M
1.42M
4.59%
17.13%
2.99%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
SOLANA BEACH